Chinese guideline for clinical diagnosis and treatment of malignant pleural mesothelioma (2021 Edition) / 中华肿瘤杂志
Chinese Journal of Oncology
; (12): 383-394, 2021.
Article
in Zh
| WPRIM
| ID: wpr-877503
Responsible library:
WPRO
ABSTRACT
Malignant pleural mesothelioma (MPM) is a pleura-derived malignant tumor, with a gradually increasing incidence in recent years based on domestic and foreign epidemiologic data. Most patients with MPM are diagnosed at an advanced stage due to its insidiousness and aggressiveness. The therapeutic strategies of MPM mainly include surgery, chemotherapy and radiotherapy. Recently, the immunotherapy has altered the treatment pattern and further improved the survival of these patients. In order to timely present the domestic and foreign progress in the diagnosis and treatment of MPM, and to further improve the level of standardized diagnosis and treatment in MPM in China, this guideline was formulated on the basis of existing clinical research evidence combined with experts' opinions. The guideline covers the epidemiology, diagnosis, pathology, treatment and follow-up of MPM.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Pleural Neoplasms
/
China
/
Mesothelioma, Malignant
/
Immunotherapy
/
Lung Neoplasms
/
Mesothelioma
Type of study:
Diagnostic_studies
/
Guideline
Limits:
Humans
Country/Region as subject:
Asia
Language:
Zh
Journal:
Chinese Journal of Oncology
Year:
2021
Type:
Article